Hematologic Malignancy
Monoclonal Immunoglobulin Deposition Disease
CI-CAN-00006049Explore in graph →
HematologicNon-malignant37 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006049Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT00536601 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
| completed |
| N/A |
| 174 |
| Roswell Park Cancer InstituteOTHER |
| 1 |
| Apr 22, 2021 |
| clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04612582 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | unknown | Phase 4 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01083316 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis | completed | Phase 2 | 35 | Boston Medical CenterOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT01570387 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Boston Medical CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT02555969 | Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | completed | — | 56 | Tufts Medical CenterOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis | terminated | Phase 1 | 3 | Tufts Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT01222260 | Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis | completed | Phase 2 | 40 | Columbia UniversityOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00651937 | Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02603172 | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis | terminated | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | terminated | Phase 2 | 34 | Prothena Biosciences Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02574676 | Quality of Life (QOL) Registry for Patients With AL Amyloidosis | completed | — | 343 | Prothena Biosciences Ltd.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | terminated | Phase 3 | 3 | Boston Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02791373 | Vinorelbine and Gemcitabine in Myeloma(ViGeM) | completed | Phase 2 | 136 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT01677286 | Safety and Effect of Doxycycline in Patients With Amyloidosis | completed | Phase 2 | 25 | Boston UniversityOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01406314 | SAP Depleter Dose Assessment Study in Patients | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01194791 | Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed(LENDEXAL) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00890552 | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | completed | N/A | 25 | Stanford UniversityOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT01277016 | A Trial for Systemic Light-chain (AL) Amyloidosis(EMN-03) | completed | Phase 3 | 110 | European Myeloma Network B.V.NETWORK | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | completed | — | 99 | Daniel BernsteinOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT02257905 | Allo SCT in Amyloidosis Non-interventional Study | completed | — | 14 | European Society for Blood and Marrow TransplantationNETWORK | 3 | Jul 24, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00919139 | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | completed | — | 190 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2015 | clinicaltrials |
| NCT01072773 | Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01998503 | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | completed | Phase 3 | 56 | Nanjing University School of MedicineOTHER | 1 | Nov 29, 2013 | clinicaltrials |
| NCT00883623 | A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis(LEOMEX) | completed | Phase 2 | 50 | Heidelberg UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00807872 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 40 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT01815086 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | completed | Phase 1 | 30 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01409148 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 38 | University of TennesseeOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00017680 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | completed | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2008 | clinicaltrials |
| NCT00344526 | Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | completed | Phase 3 | 100 | University Hospital, LimogesOTHER | 1 | Jun 28, 2007 | clinicaltrials |
Data updated 22 days agoSource updated May 7, 2021source: clinicaltrials